Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report

Rhea-AI Summary

Agenus (NASDAQ: AGEN) will release its Q4 and full year 2020 financial results on March 15, 2021, before market open. The company focuses on immuno-oncology, leveraging a strong pipeline of therapies to activate immune responses against cancers and infections. Following the results announcement, executives will host a conference call at 8:30 a.m. ET to discuss the outcomes and provide a corporate update. Interested parties can access the live webcast via the company’s website.

Positive

• Upcoming release of Q4 and full year 2020 financial results indicates transparency.
• Strong focus on immuno-oncology with an extensive pipeline of therapies.

Negative

• None.

Conference Call on Monday, March 15, 2021 at 8:30 a.m. ET

LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarter and full year 2020 financial results before the market opens on Monday, March 15, 2021. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.

Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International); Conference ID: 2339028.

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/3f7iind8.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

When will Agenus release its Q4 2020 financial results?

Agenus will release its Q4 2020 financial results on March 15, 2021, before market opening.

What time is the conference call for Agenus Q4 2020 results?

The conference call for Agenus Q4 2020 results is scheduled for 8:30 a.m. ET on March 15, 2021.

How can I listen to the Agenus conference call?

You can listen to the Agenus conference call via a live webcast on the company's Events & Presentations page on their website.

What is the focus area of Agenus?

Agenus is focused on immuno-oncology, developing therapies that engage the immune system to fight cancer.